The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

- dronedarone (C01BD07),

- erythropoietin (B03XA01),

- Glatiramer (L03AX13),

- Ibuprofen (M01AE01 & M02AA13),

- Levodopa & Benserazide (N04BA11),

- methocarbamol (M03BA03),

- metoclopramide (A03FA01),

- propiverine (G04BD06),

- Timolol & Latanoprost (S01ED61),

- tiotropium (R03BB04),

- valproic acid (N03AG01),

- zolmitriptan (N02CC03).

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to standardized contractual conditions and a standardized access procedure.

The earliest contract start is June 1st, 2021. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is June 1st, 2021. Based on this, the contract term is a maximum of 24 months.